首页> 外国专利> Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or sialyl-Lewis. sup.a

Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or sialyl-Lewis. sup.a

机译:E-选择蛋白或P-选择蛋白与唾液酸化Lewis.x或唾液酸化-路易斯的结合。速霸

摘要

This invention relates to compounds that inhibit the binding of E- selectin and/or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis. sup.a presented on a cell surface having the general structure ##STR1## wherein X is selected from the group consisting of --(CH.sub.2).sub.n CO. sub.2 H, --O(CH.sub.2).sub.m CO.sub.2 H, --(CH.sub.2).sub.n O(CH.sub.2). sub.m CO. sub.2 H, --CONH(CH.sub.2).sub.m CO.sub.2 H, --CH(OZ)(CO.sub.2 H) , --CH(Z) (CO.sub.2 H), --(CH.sub.2).sub.n SO.sub.3 H, --(CH.sub.2).sub.n PO.sub.3 D.sub.1 D.sub.2, --NH(CH.sub.2).sub.m CO.sub.2 H, --CONH(CHR.sub. 6)CO.sub. 2 H, (1-H-tetrazolyl-5-alkyl-), and --OH;PPR. sub.1 and R. sub.2 are independently selected from the group consisting of hydrogen, alkyl, halogen, --OZ, --NO.sub.2, --NH.sub.2 and --NHZ; PP R.sub.3 is selected from the group consisting of hydrogen, halogen, alkyl, --OZ and --NHZ;PPR.sub.4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxyl, hydroxyl-O- sulfate and - -OZ;PPR.sub.5 is selected from the group consisting of hydroxyl, --CN, --N.sub.3, --NH.sub.2, --NHNH.sub.2, --NE. sub.1 E.sub.2, - -NHE.sub.1, --NHCO(CH.sub.2).sub.n CO.sub.2 H, --S(CH. sub.2).sub.m CO.sub. 2 H and --NHCHNHNH.sub.2 ;PPR.sub.6 is selected from the group consisting of hydrogen, alkyl, aralkyl, hydroxyalkyl, aminoalkyl, alkyl carboxylic acid and alkyl carboxamide; PPwherein n is 0 to 6, m is 1 to 6, p is 0 to 6, b is 0 to 2, Z is alkyl, aryl or aralkyl, D.sub.1 and D.sub.2 are independantly hydrogen or alkyl, E.sub.1 is alkyl or --(CH.sub.2).sub.8 CO.sub.2 H, and E.sub.2 is alkyl, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. This invention also relates to methods of inhibiting the binding of E- selectin and/or P-selectin to sialyl-Lewis. sup.x or sialyl-Lewis.sup.a presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E- selectin to sialyl-Lewis.sup.x and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occur following heart attacks, strokes and organ transplants.
机译:本发明涉及抑制E-选择蛋白和/或P-选择蛋白与唾液酸化-Lewis x或唾液酸化-Lewis结合的化合物。呈现在具有通用结构## STR1 ##的细胞表面上,其中X选自-(CH.sub.2).n。CO.sub.2 H,--O( CH.sub.2)sub.m CO.sub.2 H,-(CH.sub.2)n.O(CH.sub.2)。 sub.m CO。sub.2 H,--CONH(CH.sub.2).sub.m CO.sub.2 H,--CH(OZ)(CO.sub.2 H),--CH( Z)(CO.sub.2 H),-(CH.sub.2)n SO.sub.3 H,-(CH.sub.2)n。PO.sub.3 D sub.1 D.sub.2,--NH(CH.sub.2)sub.m CO.sub.2 H,--CONH(CHR.sub.6)CO.sub。 2 H,(1-H-四唑基-5-烷基-)和-OH; P R。子1和R.2独立地选自氢,烷基,卤素,-OZ,-NO.2,-NH.2和-NHZ;

R 3选自氢,卤素,烷基,-OZ和-NHZ;

R 4选自氢,卤素,烷基,羟基,羟基-O-硫酸盐和--OZ; P 5选自羟基,-CN,-N 3,-NH .sub.2,-NHNH.sub.2,-NE。 sub.1 E.sub.2,--NHE.sub.1,--NHCO(CH.sub.2).sub.n CO.sub.2 H,--S(CH。sub.2).sub。 .m CO.sub。 2 H和-NHCHNHNH 2; P> R 6选自氢,烷基,芳烷基,羟烷基,氨基烷基,烷基羧酸和烷基羧酰胺; P>其中n为0至6,m为1至6,p为0至6,b为0至2,Z为烷基,芳基或芳烷基,D 1和D 2独立地为氢或烷基,E.sub.1是烷基或-(CH.sub.2).8 CO.sub.2 H,并且E.sub.2是烷基,以及药学上可接受的盐,酯,酰胺和其前药。本发明还涉及抑制E-选择蛋白和/或P-选择蛋白与唾液酸化-刘易斯结合的方法。使用所述化合物在细胞表面上呈递的supra.x或sialyl-Lewis.a和包含抑制E-选择蛋白与sialyl-Lewis.x的结合的化合物的药物活性组合物以及治疗败血性休克的方法,ARDS,克罗恩病,牛皮癣和类风湿关节炎等慢性炎症性疾病,以及心脏病发作,中风和器官移植后发生的再灌注损伤。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号